| Name | Title | Contact Details |
|---|---|---|
Julie Cox |
Manager Human Resources | Profile |
Amanda Robinson |
Vice President of Global Marketing | Profile |
Michael Ngan |
Director Finance | Profile |
Jill Maiola |
Vice President, Global Supply Chain | Profile |
Paola Wisner |
Vice President, Global Research & Development | Profile |
Discovery Laboratories, Inc. is a specialty biotechnology company focused on advancing a new standard in respiratory critical care. Discovery Labs` technology platform includes its novel proprietary KL4 surfactant, a synthetic, peptide-containing surfactant that is structurally similar to pulmonary surfactant, and its proprietary drug delivery technologies being developed to enable efficient delivery of aerosolized KL4 surfactant and other inhaled therapies. Discovery Labs` strategy is initially focused on neonatology and improving the management of respiratory distress syndrome (RDS) in premature infants. Discovery Labs believes that its RDS product portfolio has the potential to become the new standard of care for RDS and, over time, enable the treatment of a significantly greater number of premature infants who could benefit from surfactant therapy that are currently not being treated. In many pulmonary diseases, including RDS, acute lung injury (ALI), and other respiratory conditions, surfactant is either deficient or may fail to function properly. Our precision-engineered, peptide-containing KL4 surfactant has been designed to mimic the essential function of human pulmonary surfactant and may have the potential to address conditions such as these. We are developing our proprietary delivery technologies to one day enable efficient, targeted upper-respiratory or alveolar delivery of our KL4 surfactant in aerosolized form to allow for a gentler, less invasive delivery approach. These same delivery systems may also potentially be used to deliver a variety of additional aerosolized medicines safely and in a simplified way compared with the current standard of care.
Project House is a Hackensack, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
RBC Product Development is a Lenexa, KS-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Allegiance Life is a Missoula, MT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
At Carolina Pines Regional Medical Center, we "care for our own, right here at home." A leader in providing quality health care services to the people of several counties in northeastern South Carolina, patients have come to rely on our experienced, skilled staff and physicians to provide them with the highest level of care and compassion. Through the facilities on our campus, including a 116-bed acute care hospital and an adjoining medical office building, we provide comprehensive services with two things in mind: the care and comfort of our patients. From routine checkups to complex, state of the art surgery, Carolina Pines Regional Medical Center wants to be your health care provider of choice. Our goal is to be valued for our leadership, expertise and the ability to positively impact the quality of life for the citizens in our service area which includes Darlington, Chesterfield, Lee and Marlboro Counties. It is our privilege to care for our own, right here at home. This hospital is partially owned by physicians.